Individual biological variation plays a significant role in treatment response
Zepbound (tirzepatide) is FDA-approved for weight loss and chronic weight management in obese individuals (body mass index, BMI 30 or above) and in overweight individuals (BMI 25 to 30) with at least one weight-related medical condition, such as high blood pressure, high cholesterol, or type 2 diabetes
When the stomach and intestinal wall are distended and blood sugars increase (such as after Thanksgiving dinner), GLP-1 is released, stimulating the terminal ends of the vagus nerve
References Li J, Li K, Liu Z, Yu H, Zhang J
Different eligibility, different funding routes, different review requirements
Step 4: Prescription and Pharmacy Fulfillment Approved prescriptions go to a licensed pharmacy for brand-name Zepbound or Mounjaro, or to a state-regulated compounding pharmacy when appropriate